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SAHA is a class I HDAC/HDAC6 co-inhibitor and an autophagy inducer currently
undergoing clinical investigations in breast cancer patients. However, the molecular
mechanism of action of SAHA in breast cancer cells remains unclear. In this study, we
found that SAHA is equally effective in targeting cells of different breast cancer subtypes
and tamoxifen sensitivity. Importantly, we found that down-regulation of survivin plays
an important role in SAHA-induced autophagy and cell viability reduction in human
breast cancer cells. SAHA decreased survivin and XIAP gene transcription, induced
survivin protein acetylation and early nuclear translocation in MCF7 and MDA-MB-231
breast cancer cells. It also reduced survivin and XIAP protein stability in part through
modulating the expression and activation of the 26S proteasome and heat-shock
protein 90. Interestingly, targeting HDAC3 and HDAC6, but not other HDAC isoforms,
by siRNA/pharmacological inhibitors mimicked the effects of SAHA in modulating the
acetylation, expression, and nuclear translocation of survivin and induced autophagy in
MCF7 and MDA-MB-231 cancer cells. Targeting HDAC3 also mimicked the effect of
SAHA in up-regulating the expression and activity of proteasome, which might lead to
the reduced protein stability of survivin in breast cancer cells. In conclusion, this study
provides new insights into SAHA’s molecular mechanism of actions in breast cancer cells.
Our findings emphasize the complexity of the regulatory roles in different HDAC isoforms
and potentially assist in predicting the mechanism of novel HDAC inhibitors in targeted
or combinational therapies in the future.
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INTRODUCTION
HDAC inhibitors, such as suberoylanilide hydroxamic acid
(SAHA, Vorinostat) and Trichostatin A (TSA), have been shown
to exhibit pleiotropic anticancer activities in many preclinical
and clinical investigations of human cancers (Vigushin et al.,
2001; Kelly et al., 2003; Roh et al., 2004; Condorelli et al.,
2008). Among different HDAC inhibitors, SAHA is a class I
HDAC/HDAC6 co-inhibitor that has already been approved
by the U.S. Food and Drug Administration (FDA) for the
treatment of advanced cutaneous T-cell-lymphoma. Its safety and
effectiveness are also currently undergoing various Phase I/II
clinical evaluations (ClinicalTrials.gov identifier: NCT00416130,
NCT00368875, NCT01720602) in male/female patients with
breast cancer. Surprisingly, although several studies have shown
that SAHA induces autophagy, apoptosis, and exhibits potent
anti-proliferative activity in cancer cells, the exact mechanisms by
which SAHA induces these effects have not been fully understood
(Butler et al., 2002; Lee et al., 2012).
Survivin is a well-known member of the inhibitor-of-
apoptosis proteins (IAPs) family. It regulates mitosis and inhibits
both caspase-dependent and -independent apoptosis in cancer
cells (Li et al., 1998; Tamm et al., 1998; Cheung et al., 2010;
Coumar et al., 2013). Interestingly, our previous study revealed
that even though survivin is an inhibitor of apoptosis, targeting
survivin by small molecule inhibitor or by siRNA induces
autophagy and autophagic cell death in breast cancer cells
regardless of the endogenous expression of p53 and caspase-3
(Cheng et al., 2015). However, survivin is traditionally classified
as an apoptosis inhibitor; therefore, the role of survivin in
SAHA-induced autophagy and autophagic cell death in cancer
cells has seldom been investigated.
In this study, we found that SAHA down-regulates survivin
expression at both transcriptional and post-transcriptional levels
in part through HDAC2, HDAC3, and HDAC6 inhibitions. In
addition, we found that down-regulation of survivin plays an
important role in regulating SAHA induced autophagy and cell
viability reduction in breast cancer cells.
MATERIALS AND METHODS
Cell Lines and Cell Culture Conditions
Human breast adenocarcinoma cell lines MCF7 (p53 wild-type),
MDA-MB-231 (p53 mutant), and SK-BR-3 (p53 mutant) were
originally obtained from ATCC (Table 1). Briefly, MCF7 cells
were cultured in α-MEM containing 5% fetal bovine serum
(FBS), penicillin/streptomycin/glutamine (PSG), and insulin
transferrin selenium [ITS (Roche, cat# 11074547001)]. MDA-
MB-231 cells were cultured in RPMI containing 10% FBS and
PSG. SK-BR-3 cells were cultured in DMEM containing 10% FBS
and PSG. All cell lines were incubated at 37◦C in a humidified
incubator containing 5% CO2 in air and were shown to be
mycoplasma free. A series of MCF7-derived ER+/tamoxifen-
resistant breast cancer cell lines (TamC3 and TamR8) were also
used in this study. The cellular andmolecular phenotypes of these
tamoxifen-resistant breast cancer cell lines have already been
characterized in a previous study (Leung et al., 2010). TamR8
breast cancer cells were cultured in α-MEM containing 5% fetal
bovine serum (FBS), penicillin/streptomycin (10,000 unit/mL
and 10mg/mL, respectively), insulin transferring selenium
(ITS, Roche), and tamoxifen (5 µM). In contrast, TamC3
breast cancer cells were cultured in phenol-red-free RPMI
containing 5% charcoal-stripped FBS, penicillin/streptomycin
(10,000 unit/mL and 10mg/mL, respectively), and ITS
(10mg/L).
MTT Cell Viability Assay
A total of 5040 cells were seeded onto each well of 96-well plates
for 24 h prior treating with SAHA for 96 h. After treatment,
180 µL of MTT solution [mixing MTT (Amresco, cat# 0793) 5
mg/mL in phenol-red free RPMI in a ratio of 1:10] was added
to each well and incubated for 4 h. Then, 100 µL MTT lysis
buffer was added to each well and incubated for 12 h. The
absorbance of the solution was quantified by measuring at 570
nm wavelength by a spectrophotometer. The percentage cell
growth inhibition for each treatment group was calculated by
adjusting the untreated control group to 100%. All experiments
were done using duplicate wells, and repeated at least three
times.
Gene Silencing by siRNA
Target-validated siRNA oligos were transfected into MCF-7
and MDA-MB-231 breast cancer cells using Lipofectamine R©
RNAiMAX reagent (Invitrogen, cat# 13778-150). Briefly, 35
× 104 MCF7 and 25 × 104 MDA-MB-231 cells were seeded
onto 6 cm dishes, and cultured overnight in antibiotic-free α-
MEM and RPMI medium. 7.5 µL of survivin and XIAP siRNA
oligomers (Cell Signaling Technology, cat# 6351 and cat# 6446)
were diluted in 100 µL of Opti-MEM R© I medium (Gibco,
cat# 31985) without serum, and then mixed with 7.5 µL of
Lipfectamine R© RNAiMAX transfection reagent diluted in 98 µL
Opti-MEM R© I medium (Gibco) for 20min at room temperature.
Two microliters of HDAC 1, 2, 3, and 6 siRNA oligomers
(Dharmacon, cat# M-003493-02-0005, cat# M-003495-02-0005,
cat# M-003496-02-0005, and cat# M-003499-00-0005) were
diluted in 98 µL of Opti-MEM R© I medium (Gibco) without
serum, and then mixed with 2 µL of Lipfectamine RNAiMAX
transfection reagent diluted in 98 µL Opti-MEM R© I medium
(Gibco) without serum for 20min at room temperature. Cells
were overlaid with the transfection mixture, and incubated for
24–48 h.
Western Blot Analysis
Cells were lysed in CelLyticTM cell lysis reagent (Sigma,
cat# C2978) containing 1mM PMSF and 1mM NaF with
cocktail protease inhibitors (Roche, cat# 05892791001). Equal
amounts of protein were subjected to SDS-PAGE on either
an 8% or a 10% acrylamide gel. The resolved proteins were
transferred to a PVDF membrane (Millipore), which was
then exposed to 5% non-fat dried milk in TBST for 1 h at
room temperature before incubation overnight at 4◦C with
primary antibodies. The PVDF membrane was then washed
with TBS containing 0.05% Tween-20 before incubation for 1 h
at room temperature with horse-radish peroxidase—conjugated
Frontiers in Pharmacology | www.frontiersin.org 2 March 2016 | Volume 7 | Article 81
Lee et al. SAHA Inhibits Survivin Expression
TABLE 1 | Characteristics of different cancer cell lines used in the study.
Cells ER status P53 status Caspase-3 status Tamoxifen sensitivity SAHA IC50 (µM)
MCF7 Expressing Wild-type Deficient Sensitive 0.7 ± 0.1
MCF7-TamC3 Expressing Wild-type Deficient Resistant 0.9 ± 0.1
MCF7-TamR8 Expressing Wild-type Deficient Resistant 1.2 ± 0.3
MDA-MB-231 Deficient Mutant Expressing Resistant 1.6 ± 0.5
Sk-Br-3 Deficient Mutant Expressing Resistant 1.3 ± 0.5
Breast cancer cells were treated with SAHA for 4 days and cell viability was determined by MTT assay. The IC50-values (inhibitory concentrations at which 50% decrease in cell viability
is achieved) represent the average of at least three independent experiments.
goat antibodies to rabbit (Millipore, cat# AP132P), mouse
(Millipore, cat# AP124P), or goat (Millipore, cat# AP106P)
immunoglobulinG. Immunoreactive proteins were visualized
using Western blot enhanced chemiluminescence reagents and
protein signals were detected by luminescence readers (FUJI
LAS-100, Tokyo, Japan). Experiments were repeated at least
three times. Primary antibodies used in this study are listed
as follows: mouse antibodies against β-actin and acetylated
tubulin were obtained from Millipore (cat# MAB1501 and cat#
05829); antibodies against lamin A/C were from Santa Cruz
(cat# sc-7292); antibodies against proteasome 26S and Hsp90
were from Abcam (cat# AB58115-100); and Enzo (cat# SPA-830),
respectively. Goat antibodies against XIAP were obtained from
Cell Signaling Technology (cat# 6466). Rabbit antibodies against
LC3B were obtained from Origene (cat# TA301543); antibodies
against survivin were from R&D system (cat# AF886); antibodies
against acetylated survivin were from Novus (cat# NBP1-47639)
and those against HDAC1, 2, 3, and 6 were from Gene Tex
(cat# GTX100513, cat# GTX109642, cat# GTX109679, and cat#
GTX100722).
Reverse Transcription and Quantitative
PCR (qPCR)
Total RNA was extracted using TRIzol R© reagent (Invitrogen)
and complementary DNA was synthesized from RNA using the
RevertAid H Minus first strand cDNA synthesis kit (Thermo
Scientific). Expression levels of survivin, XIAP, and actin
transcript were determined by qPCR. The following primers
were used in the study: human survivin forward primer, 5′-AGA
ACTGGCCCTTCTTGGAGG; human survivin reverse primer,
5′-CTTTTTATGTTCCTCTATGGGGTC; human XIAP forward
primer, 5′-CAATATGGAGACTCAGCAGTTGGA; human
XIAP reverse primer, 5′-GCACTATTTTCAAGATAAAAGCCG
TT; human beta-actin forward primer, 5′-GGCGGCACCACC
ATGTACCCT; human beta-actin reverse primer, 5′-AGGGGC
CGGACTCGTCATACT; Experiments were repeated at least
three times.
Monodansylcadaverine (MDC) Staining of
Acidic Vesicular Organelles (AVOs) and
Immunofluorescence Staining of
Autophagosome/Autophagolysosome
MDC staining was used to detect the formation of acidic
vesicular organelles (AVOs) in breast cancer cells. Briefly, MCF7
and MDA-MB-231 cells were seeded on the 24-well plates
and treated with 1/4x, 1/2x, 1x, 2x IC50 of SAHA or 1x
IC50 of resveratrol for 72 h. AVOs were labeled with 0.5mM
MDC in the phenol red-free RPMI at 37◦C for 2 h. Then,
the cells were washed three times with PBS. To detect the
formation of autophagosome or autophagolysosome in cells,
immunofluorescence staining of LC3B was used. Briefly, MCF7
cells were seeded on glass coverslips. Cells were fixed with 4%
paraformaldehyde for 15min at room temperature and the fixed
cells were then permeabilized with PBS containing 1% triton X-
100 (Calbiochem) for 30min, subsequently blocked in 5% bovine
serum albumin (Sigma-Aldrich) for an hour and incubated with
anti-LC3B primary antibodies overnight at 4◦C. The cells were
washed three times with TBS-Tween buffer, incubated with
Alexa Fluor 594-conjugated secondary antibodies (Abcam, cat#
ab150076) for an hour at room temperature, and suspended
in blocking buffer containing DAPI for 15min. AVOs and
autophagosome/autophagolysosome in all cells were observed
under a fluorescence microscope (Olympus, IX-71). Experiments
were repeated at least three times.
Protein Stability Assay
To measure the rate of protein degradation of survivin and
XIAP, MCF7, and MDA-MB-231 cells were treated with 10
µg/mL of cycloheximide 72 h after SAHA treatment to inhibit
de novo protein synthesis. Whole cell extracts were prepared
from samples taken at 30min time interval until 120min, and
the amounts of the survivin and XIAP protein present were
determined by Western blotting. The rate of protein degradation
was relative to the untreated control. Experiments were repeated
three times.
Proteasome Activity Assay
The proteasome activity assay was performed using a proteasome
activity fluorometric assay kit (BioVision, cat# K245-100)
according to the manufacturer’s instructions. Briefly, proteasome
inhibitor MG132 and proteasome substrates were added to
the SAHA-treated cells. Samples were incubated in 37◦C for
30 min. After incubation, the kinetics of the fluorescence
development at Ex/Em = 350/440 nm were measured every
5min for 30min, and the luminescence was recorded on a
SpectraMax R© M5 microplate reader (Molecular Devices). The
proteasome activity is calculated using the following equation:
Proteasome activity =
B x sample dilution factor
(T2−T1)x V .
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Statistical Analysis
Each experiment was performed at least three times. Data
are presented as mean (mean average of the replicated
experiments) ± s.e. (standard error of the mean of the replicated
experiments). The significance of difference was evaluated with
one-way ANOVA. A value of P < 0.05 was considered to be
statistically significant.
RESULTS
SAHA Induces Autophagy and
Down-Regulates the Expression of Survivin
and XIAP in Human Breast Cancer Cells
To determine the effectiveness of SAHA in targeting various
types of breast cancer in vitro, IC50-values for SAHA were
determined. In this study, the ER+/caspase-3-deficient/p53-
expressing MCF7 and its tamoxifen-resistant sub-lines (MCF7-
TamR8 and MCF7-TamC3) were used. As shown in Table 1,
MTT cell viability assay revealed that the IC50-values of SAHA in
MCF7-TamC3 (0.9± 0.1µM) andMCF7-TamR8 (1.2± 0.3µM)
were similar to that in the parental tamoxifen-sensitive MCF7
(0.7 ± 0.1 µM) cells. SAHA was also effective in targeting SK-
BR-3 (ER−/HER2+, caspase-3, and p53 mutant-expressing) and
the triple-negative MDA-MB-231 (ER−/HER2−/PR−, caspase-
3, and p53 mutant-expressing) breast cancer cells at low
micromolar concentrations (Table 1). Taken together, our results
revealed that SAHA is effective in reducing cell viability of
various breast cancer subtypes regardless of the expression
and status of ER, HER2, caspase-3, and p53. Western blot
analysis was used to investigate the molecular effects of
SAHA in breast cancer cells. Two different breast cancer
cell lines, MCF7 (ER+/tamoxifen-sensitive) and MDA-MB-231
(ER−/HER2−/PR−/tamoxifen-resistant), were selected for the
following molecular investigations. As shown in Figure 1A,
SAHA increased the expression of acetylated α-tubulin, which is a
function indicator of the drug, in both MCF7 and MDA-MB-231
cells in a concentration-dependent manner. SAHA also increased
the conversion of LC3B-II and expression of beclin-1, and
decreased the expression of p62/SQSTM1, which are molecular
markers for autophagy (Figures 1A,B). SAHA-treated cells were
stained with monodansylcadaverine (MDC) to further determine
the formation of acidic vesicular organelles (AVOs). MDC is
a fluorescent compound commonly used for the detection of
AVOs including lysosome and autolysosome (Niemann et al.,
2000; Munafo and Colombo, 2001). Similar to the results
of cancer cells treated with the known autophagy inducer,
resveratrol, SAHA treatment also increased the formation of
green fluorescent puncta, indicating the increased formation of
AVOs (Supplementary Figure 1 and Figure 1C). Taken together,
these results indicate that SAHA, at the tested concentrations, did
function normally at the molecular level and induced autophagy
in both MCF7 and MDA-MB-231 cells. Surprisingly, cleavage of
caspase-3 and PARP, which are molecular markers for caspase-
3 activation, was only observed in the pro-caspase-3 expressing
MDA-MB-231 cells treated with high concentration (2x IC50)
of SAHA (Figure 1A), suggesting that caspase-3 activation
might only play a role in the cell viability reduction induced
by SAHA at high concentrations but not in moderate-to-low
concentrations.
Although survivin and its binding partner, XIAP, have been
known for their anti-apoptotic functions in regulating cell
survival and cell proliferation (Altieri, 2003; Potts et al., 2003),
evidence that survivin and XIAP function as an endogenous
repressor of autophagy has emerged (Wang et al., 2011; Huang
et al., 2013; Cheng et al., 2015). SAHA is a class I HDAC
(HDAC1, 2, and 3) and HDAC6 co-inhibitor and HDAC6
has been shown to regulate survivin expression through de-
acetylation and cytoplasmic retention of survivin. Therefore, to
determine whether SAHA-induced autophagy and/or decreased
cell viability were at least partially caused by altering the
expression of survivin and XIAP, the effects of SAHA on
survivin and XIAP expression in both MCF7 and MDA-MB-
231 cells were examined. Western blot analysis revealed that
SAHA decreased the expression of survivin and XIAP in both
concentration- and time-dependent manners (Figures 1A,B).
Then, we evaluated the impact of the expression of survivin
and XIAP on the effectiveness of SAHA in reducing cell
viability and up-regulating autophagy in breast cancer cells.
MTT assay revealed that ectopic over-expression of survivin
significantly attenuated the inhibitory effect of SAHA (at 1x
IC50 conc.) on cell viability in both MCF7 and MDA-MB-231
cells (Figure 2A). Surprisingly, ectopic over-expression of XIAP
only attenuated the cell viability inhibitory effect of SAHA in
MCF7 but not in MDA-MB-231 breast cancer cells (Figure 2A).
In addition, down-regulation of XIAP alone by siRNA did not
affect the viability of MDA-MB-231 cells in vitro (Figure 2B).
These results indicated that XIAP might only play a minor
role and/or a cell line-dependent role in SAHA-induced cell
viability reduction, whereas, survivin might play a major role
in facilitating SAHA induced cell viability reduction in human
breast cancer cells.
Because down-regulation of survivin by siRNA induced
autophagy as indicated by the decreased expression of
p62/SQSTM1 and increased conversion of LC3B-II in both
MCF7 and MDA-MB-231 cells (Figure 2C), experiments were
carried out to determine whether survivin down-regulation
plays a role in SAHA-induced autophagy, which contributes
to the subsequent cell death. Ectopic over-expression of
survivin was performed and changes in the expression of
p62/SQSTM1 and the formation of autophagosome in the
SAHA-treated MCF7 cells was analyzed by Western blotting
and immunofluorescence microscopy. As shown in Figure 2D,
SAHA treatment (at 1x IC50 conc.) decreased the expression of
p62/SQSTM1, which is an autophagic flux marker, in MCF7 cells
as expected. SAHA treatment also increased the formation of
LC3B (red fluorescent) puncta, indicating increased formation
of autophagosome/autophagolysosome in cells (Figure 2E).
Noticeably, ectopic over-expression of survivin partially restored
the expression of p62/SQSTM1 and attenuated the effect of
SAHA on LC3B puncta formation in the SAHA-treated cells
(Figures 2D,E). Taken together, these results indicate that SAHA
upregulates autophagy partially through down-regulation of
survivin.
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FIGURE 1 | SAHA concurrently induces autophagy and down-regulates the expression of survivin and XIAP in human breast cancer cells. (A,B) MCF7
and MDA-MB-231 cells were treated with SAHA and expression of different proteins was analyzed by Western blotting. Equal protein loading was verified by actin.
Experiments were repeated three times. The numbers under each blot are intensity of the blot relative to that of the untreated control (either “–ve control” or “0 h”).
Signals in the survivin and XIAP blots (of all repeats) were quantitated and a graph was generated to show the effect of SAHA on the expression of survivin and XIAP. A
statistically significant difference in the expression of survivin and XIAP in cells treated with SAHA vs. without SAHA (either “–ve control” or “0 h”) is denoted by “*” (p <
0.05) and “**” (p < 0.01). (C) MCF7 and MDA-B-231 breast cancer cells were treated with various concentrations of SAHA for 72 h and subsequently stained with
MDC. AVOs in cells were observed under a fluorescence microscope. Red arrows indicate puncta formation.
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FIGURE 2 | Survivin plays an important role in SAHA-induced autophagy in breast cancer cells. (A, upper panels) MCF7 and MDA-MB-231 cells were
transfected with either pCMV-XL (control), pCMV-XL4-survivin [overexpresses (O/E) survivin] or pCMV-XL-5-XIAP (O/E XIAP) plasmid for 72 h. Expression of different
proteins was analyzed by Western blotting. (A, lower panels) MCF7 and MDA-MB-231 cells were transfected with pCMV-XL (control), pCMV-XL4-survivin (O/E survivin)
or pCMV-XL-5-XIAP (O/E XIAP) for 24 h prior to 72 h SAHA treatment. Cell viability was assessed by MTT assay. Experiment was repeated three times. A statistically
significant difference in the viability of cells treated with O/E survivin or O/E XIAP + SAHA vs. SAHA alone is denoted by “*” (p < 0.05). “N.S.,” denotes no significant
difference between the testing groups. (B) MDA-MB-231 cells were treated with either scramble siRNA or XIAP-specific siRNA (si-XIAP) for 72 h and cell viability was
analyzed by MTT assay. (C) MCF7 cells were treated with either scramble siRNA or survivin-specific siRNA (si-Survivin) for 72 h. Expression of various proteins was
analyzed by Western blotting. The numbers under each survivin blot are intensity of the blot relative to that of the scramble control. Signals in the p62/SQSTM1 blots
(of all repeats) were quantitated and a graph was generated to show the effect of survivin on the expression of p62/SQSTM1. (D) Cells were transfected with
pCMV-XL (control) for 72 h, pCMV-XL (control) for 24 h followed up with 48 h SAHA co-treatment, or pCMV-XL4-survivin (O/E survivin) for 24 h followed up with 48 h
SAHA co-treatment. Expression of p62/SQSTM1 was analyzed by Western blotting. (E) Cells were transfected with pCMV-XL (control) for 72 h, pCMV-XL (control) for
24 h followed up with 48 h SAHA co-treatment, or pCMV-XL4-survivin (O/E survivin) for 24 h followed up with 48 h SAHA co-treatment. Formation of LC3B (red
fluorescent) puncta in cells was observed under a fluorescence microscope and pointed out by the arrows in the photos. Nuclei were counterstained blue with DAPI.
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FIGURE 3 | SAHA affects the expression of suvivin and XIAP at the transcriptional level. (A) MCF7 and (B) MDA-MB-231 cells were treated with various
concentrations of SAHA for 24 h. The relative amount of survivin and XIAP mRNA transcripts present in cells was analyzed by qPCR. Experiment was repeated three
times. A statistically significant difference in the amount of mRNA transcripts present in cells treated with SAHA vs. without SAHA (negative control) is denoted by “*”
(p < 0.05) and “**” (p < 0.01). (C) MCF7 cells were treated with SAHA for 24 h and expression of p53 was determined by Western blotting. (D) MCF7 cells were
transfected with HDAC1, 2, 3, or 6 siRNA for 48 h. Expression of different proteins was analyzed by Western blotting. Signals in the survivin blots (of all repeats) were
quantitated and a graph was generated to show the effect of different HDACs on the expression of survivin. (E) MCF7 cells were transfected with scramble, HDAC2,
3, or 6 siRNA for either 24 or 48 h. Relative amount of survivin mRNA transcripts present in cells was determined by qPCR. Experiment was repeated three times. A
statistically significant difference in the amount of mRNA transcripts present in cells treated with HDAC2, 3, or 6 siRNA vs. scramble siRNA is denoted by either “*”
(p < 0.05) or “**” (p < 0.01).
SAHA Decreases the Amount of Survivin
and XIAP mRNA Transcripts Present in
Breast Cancer Cells
Next, we sought to investigate which pathway could SAHA
be involved in suppressing the expression of survivin and
XIAP; we examined the effects of SAHA on survivin and
XIAP at the transcriptional level. Quantitative real-time PCR
analysis revealed that SAHA (24 h post-treatment, at 1–2x
IC50 conc.) decreased the amount of survivin and XIAP
mRNA transcripts present by approximately 50% in both
MCF7 and MDA-MB-231 cells (Figures 3A,B), indicating that
SAHA, at least at the tested concentrations, can reduce
the expression of survivin and XIAP at the transcriptional
level. In addition, Western blot analysis revealed that SAHA
did not affect the expression of p53, which is a survivin
gene transcription negative regulator, in the wild-type p53
expressing MCF7 cells, further indicating that SAHA exhibits
its anti-breast cancer effect, at least at the transcriptional level,
through a p53-independent mechanism (Figure 3C; Mirza et al.,
2002).
To identify which isoforms of HDACs are the major
contributors in SAHA-mediated survivin depletion at the
transcriptional level, we treated the cells with HDAC1, HDAC2,
HDAC3, and HDAC6 specific siRNA. Results of theWestern blot
analysis revealed that down-regulation of HDAC2, HDAC3, and
HDAC6 decreased the expression of survivin, whereas down-
regulation of HDAC1 increased the expression of survivin in
MCF7 cells (Figure 3D). Down-regulation of HDAC1 by siRNA
also increased the expression of survivin in MDA-MB-231 cells
(Supplementary Figure 2A). Therefore, quantitative real-time
PCR was performed to determine whether HDAC2, HDAC3, and
HDAC6 (but not HDAC1) can regulate survivin gene expression
in breast cancer cells. Down-regulation of HDAC6 by siRNA did
not significantly alter the amount of survivin mRNA transcripts
present in MCF7 cells, whereas, down-regulation of HDAC2 and
HDAC3 significantly decreased the amount of survivin mRNA
transcripts present in cells (Figure 3E). Collectively, these results
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indicate that SAHA might down-regulate survivin expression at
the transcriptional level in part through HDAC2 and HDAC3
co-inhibitions.
SAHA Promotes the Degradation of
Survivin Protein in Human Breast Cancer
Cells in Part through Survivin Acetylation
and Nuclear Translocation
To determine whether SAHA also affects the expression of
survivin and XIAP through other mechanisms, the protein
stability of both survivin and XIAP was evaluated. Western
blot analysis revealed that the protein stability of survivin
was significantly decreased in both MCF7 and MDA-MB-231
cells treated with SAHA (at IC50 conc.) relative to the control
(Figure 4A). The protein stability of XIAP was also significantly
decreased in SAHA-treated MDA-MB-231 cells and slightly
decreased in SAHA-treated MCF7 cells as compared to that of
the untreated cells (Figure 4A).
Survivin shuttles between the nucleus and the cytoplasm
through active nucleocytoplasmic transport (Connell et al.,
2008). Among different HDAC isoforms, HDAC6 has been
shown to play a role in the de-acetylation and cytoplasmic
retention of survivin in cancer cells. Acetylation of the lysine
129 (K129) residue of survivin promotes nuclear translocation
of survivin, and nuclear survivin has been shown to exhibit
reduced protein stability as compare to the cytosolic survivin
(Wang et al., 2010). Therefore, we sought to determine whether
SAHA down-regulates survivin expression partially through
survivin acetylation and nuclear translocation. Here, results
from the protein stability assay by treating MCF7 with the
de novo protein synthesis inhibitor, cycloheximide, revealed
that the stability of the nuclear survivin protein was lower
than that of the cytosolic survivin protein, which is consistent
with the findings of previous studies (Figure 4B). Western blot
analysis also revealed that SAHA promoted the acetylation of
survivin in MCF7 cells in a concentration-dependent manner
(Figure 4C). To further confirm that SAHA treatment did
induce survivin nuclear translocation in the treated breast cancer
cells, immunofluorescence microscopy was performed. Results
from the immunofluorescence microscopy showed that SAHA
promoted survivin nuclear accumulation in both MCF7 and
MDA-MB-231 cells at 12–24 h post-treatment (Figure 4D). To
identify which isoforms of HDAC are the major contributors in
SAHA-mediated survivin acetylation and nuclear translocation,
we treated the cells with HDAC1, HDAC2, HDAC3, and
HDAC6 specific siRNA. Here, results of the Western blot
analysis showed that down-regulation of HDAC6 induced
survivin acetylation as expected (Figure 4E). Interestingly,
down-regulation of HDAC3 also induced survivin acetylation in
MCF7 cells (Figure 4E). To confirm that HDAC6 and HDAC3
could regulate survivin acetylation in breast cancer cells, MCF7
cells were treated with BML281 and RGFP966, which are
pharmacological inhibitors of HDAC6 and HDAC3, respectively,
and the expression of acetylated survivin was again determined
by Western blotting. Similar to the results of cells treated
with HDAC6 siRNA and HDAC3 siRNA, inhibiting HDAC6
and HDAC3 by pharmacological inhibitors also increased the
expression of acetylated survivin in MCF7 cells (Figure 4F).
Immunofluorescence microscopy was performed to confirm the
promotion of nuclear translocation of survivin in cells with
HDAC3 and HDAC6 down-regulations. Here, down-regulation
of HDAC6 and HDAC3 by siRNA clearly induced survivin
nuclear accumulation inMCF7 cells (Figure 4G). Taken together,
these results indicate that SAHA decreases survivin protein
stability at least partially through HDAC3 and HDAC6 regulated
survivin acetylation and nuclear translocation.
SAHA Increases 26S Proteasome
Expression and Decreases Hsp90
Expression in Breast Cancer Cells
Survivin expression is also post-translationally regulated by the
proteasomal protein degradation pathway. Binding of Hsp90
prevents survivin undergoing ubiquitination and the subsequent
protein degradation by proteasome (Fortugno et al., 2003).
To determine whether SAHA affects the cellular proteasomal
protein degradation pathway, leading to the reduction of survivin
protein stability in breast cancer cells, the expression of 26S
proteasome and Hsp90 in SAHA treated breast cancer cells was
determined.Western blot analysis was first performed to confirm
the importance of proteasome in regulating survivin expression
in breast cancer cells. Here, inhibiting proteasome by MG132
clearly increased survivin expression in both MCF7 and MDA-
MB-231 cells, confirming that survivin expression is regulated
post-translationally by proteasome (Figure 5A). Western blot
analysis and proteasome activity assay revealed that SAHA
treatment increased both the expression and activity of 26S
proteasome in breast cancer cells (Figures 5B,C). In contrast, the
same treatment decreased the expression of Hsp90 in MCF7 cells
(Figure 5D). Interestingly, down-regulation of HDAC3, but not
other HDAC isoforms, by siRNA increased the expression of 26S
proteasome in breast cancer cells (Figure 5E). In addition, similar
to the results of cells treated with SAHA, inhibiting HDAC6 by
BML281 also down-regulated the expression of Hsp90 in both
MCF7 and MDA-MB-231 cells, indicating that SAHA might
down-regulate Hsp90 expression through HDAC6 inhibition
(Figure 5F). Collectively, these results indicated that SAHA
might promote survivin protein degradation in part through
decreasing the ubiquitination protection fromHsp90 viaHDAC6
inhibition and increasing the expression of 26S proteasome via
HDAC3 inhibition in breast cancer cells.
DISCUSSION
Autophagy is a double-edged sword. It promotes cell survival
in cells under genotoxic stress, metabolic stress, and energy
starvation (Ogata et al., 2006; Qiang et al., 2013). However,
excessive or prolonged autophagy may reduce cell viability by
promoting autophagic cell death (Baehrecke, 2005; Szlosarek,
2014; Wang et al., 2015). Several studies have shown that
SAHA induces autophagy, apoptosis, and exhibits potent
anti-proliferative activity in cancer cells; however, the exact
mechanisms by which SAHA induces these effects have not been
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FIGURE 4 | SAHA decreases the protein stability of survivin and XIAP in breast cancer cells. (A) Breast cancer cells were treated with 1x IC50 SAHA for 72 h.
Cycloheximide (CHX) was added 72 h post-SAHA treatment to the cells to inhibit de novo protein synthesis. Cells were then harvested at the time points indicated and
expression of survivin and XIAP was analyzed by Western blotting. Experiments were repeated three times and representative blots were shown. Signals in the
(Continued)
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FIGURE 4 | Continued
blots (of all repeats) were quantitated and a graph was generated to compare the degradation rates. A statistically significant difference in the mean of the relative band
intensity (of all repeats) of survivin and XIAP in cells treated with SAHA vs. without SAHA (control) at the same time point is denoted by “*” (p < 0.05), “**” (p < 0.01), or
“***” (p < 0.001). (B) MCF7 cells were treated with cycloheximide to inhibit the de novo protein synthesis process. Nucleic proteins and cytoplasmic proteins were
isolated using cells fractionation assay. Expression of survivin was analyzed by Western blotting. Equal protein loading was verified by either lamin A/C or GAPDH. The
numbers under each blot are intensity of the blot relative to that of the control (0 h). Signals in the blots (of all repeats) were quantitated and a graph was generated to
compare the degradation rates. A statistically significant difference in the mean of the relative band intensity (of all repeats) of nuclear survivin and cytosolic survivin is
denoted by “*” (p < 0.05). (C) MCF7 cells were treated with SAHA and expression of the acetylated survivin was analyzed by Western blotting. (D) Breast cancer cells
were treated with 2x IC50 SAHA for 24 h. Intracellular distribution of survivin was analyzed using immunofluorescence confocal microscopy. Nucleus was stained blue
with DAPI. Survivin was labeled red in the photo. Relative expression of nucleic and cytoplasmic survivin in cells treated with/without SAHA was quantified. Experiment
was repeated three times. A statistically significant difference in the nucleus/cytoplasm ratio of red fluorescence (survivin) intensity in cells with SAHA vs. without SAHA
(control) is denoted by either “**” (p < 0.01) or “***” (p < 0.001). Percentage of cells with red fluorescence signal higher in the nucleus than in the cytosol in cells treated
with or without SAHA was also quantified. (E) MCF7 cells were transfected with HDAC1, 2, 3, or 6 siRNA for 36 h. Expression of acetylated survivin was determined
by Western blotting. Signals in the acetylated survivin blots (of all repeats) were quantitated and a graph was generated to show the effect of different HDAC isoforms
on the expression of acetylated survivin. A statistically significant difference in the expression of acetylated survivin in cells treated with HDAC1, 2, 3, or 6 siRNA vs.
scramble siRNA is denoted by “*” (p < 0.05). (F) MCF7 cells were treated with or without BML281 and RGFP966 for 48 h. Expression of acetylated survivin was
determined Western blotting. (G) MCF7 cells were transfected with scramble, HDAC3 or HDAC6 siRNA for 36 h. Intracellular distribution of survivin was analyzed
using immunofluorescence confocal microscopy. Nucleus was stained blue with DAPI. Survivin was labeled red in the photo. Relative expression of nucleic and
cytoplasmic survivin in cells treated with scramble, HDAC3 or HDAC6 siRNA was quantified. Experiment was repeated three times. A statistically significant difference
in the nucleus/cytoplasm ratio of red fluorescence (survivin) intensity in cells treated with HDAC3 or 6 siRNA vs. scramble siRNA is denoted by “**” (p < 0.01).
Percentage of cells with red fluorescence signal higher in the nucleus than in the cytosol in cells treated with or without HDAC3 and HDAC6 siRNA was also quantified.
fully understood (Butler et al., 2002; Lee et al., 2012). Survivin and
XIAP are members of the IAPs and traditionally, these molecules
are only believed to play important roles in regulating mitosis
and inhibiting apoptosis. Therefore, it is seldom thought that
survivin and XIAP play a role in SAHA-induced autophagy in
cancer cells. Our previous study revealed that targeting survivin
by its pharmacological inhibitor, YM155, induces autophagy
and autophagic cell death without caspase-3 activation in breast
cancer cells, indicating that: (1) caspase-3 activation is not a
definite prerequisite event for YM155 induced breast cancer
cell death and (2) survivin might play a role in the regulation
of cellular autophagy (Cheng et al., 2015). In this study, we
found that SAHA is equally potent toward the caspase-3 deficient
MCF7 cells and its tamoxifen-resistant sublines, and the caspase-
3 expressing MDA-MB-231 cells in vitro. We also found that
SAHA down-regulated survivin and XIAP expression in both
MCF7 and MDA-MB-231 breast cancer cells. Importantly, we
demonstrated that ectopic expression of survivin completely
attenuated the effect of SAHA on cell viability reduction and also
partially attenuated the effect of SAHA on autophagy induction.
The role of XIAP in SAHA-induced autophagy and SAHA-
reduced cell viability in cancer cells remains controversial. In this
study, SAHA clearly induced XIAP down-regulation in the tested
cell lines. However, ectopic over-expression of XIAP attenuated
the effect of SAHA only in MCF7 but not in MDA-MB-231 cells.
Interestingly, down-regulation of XIAP alone by siRNA did not
affect the viability of MDA-MB-231 cells. In fact, Sensintaffar
et al. also demonstrated that down-regulation of XIAP was
ineffective in reducing the cell viability of various cancer cell
lines including MCF7, HCT116 (colon), and PC3 (prostate) in
vitro (Sensintaffar et al., 2010). It is also worth noting that down-
regulation of HDAC2, 3, and 6 by siRNA all decreased survivin
expression and concurrently increased LC3B-II conversion in
MCF7 and MDA-MB-231 cells (Supplementary Figure 2B). In
contrast, down-regulation of HDAC1 decreased XIAP expression
in MCF7 and MDA-MB-231 cells, but the same treatment
increased survivin expression and concurrently decreased LC3B-
II conversion in cells (Supplementary Figures 2A,B). Taken
together, it seems that induction of autophagy, at least as
indirectly indicated by the increased conversion of LC3B-II, only
occurred in breast cancer cells with survivin down-regulation
but not with XIAP down-regulation following the knockdown of
different HDAC isoforms by siRNA. Therefore, unlike survivin,
XIAP may only play a minor and also a cell line-dependent role
in SAHA-induced autophagy and cell viability reduction in breast
cancer cells.
Although SAHA is a class I HDAC and HDAC6 co-inhibitor,
SAHA still exerts selectivity toward different HDAC isoforms.
Through in vitro HDAC activity assay, SAHA was reported to
be more effective in targeting HDAC6 (IC50 = 0.009 µM) and
HDAC3 (IC50 = 0.019 µM; Hanson et al., 2013). In addition,
targeting either HDAC3 or HDAC6 could also decrease the
expression of survivin and increased the conversion of LC3-
B-II in mutant p53-expressing SK-BR-3 breast cancer cells,
further supporting the role of HDAC3 and HDAC6 in regulating
survivin expression in the SAHA treated breast cancer cells
regardless to the p53 status (Supplementary Figure 3). It has
been shown that HDAC6 plays an important role in survivin
deacetylation and the subsequent nuclear export of survivin
(Riolo et al., 2012). Therefore, it is not surprising to see that
SAHA induced survivin acetylation and nuclear accumulation in
MCF7 and MDA-MB-231 breast cancer cells in this study, given
that SAHA is most potent in targeting HDAC6. However, it is
interesting to see that down-regulation of HDAC3 (the second
most selected target of SAHA) by siRNA also induced survivin
acetylation and nuclear translocation in breast cancer cells. In
fact, regulation of survivin acetylation and nuclear translocation
by HDAC isoform other than HDAC6 has not been shown in the
past. Furthermore, down-regulation of HDAC3 by siRNA also
mimicked the effect of SAHA in modulating survivin expression
at the transcriptional level in MCF7 cells. A study by Jung et al.
showed that 1-stearoyl-sn-glycero-3-phosphocholine (LPC), one
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FIGURE 5 | SAHA increases the expression of 26S proteasome and decreases the expression of Hsp90 in breast cancer cells. (A) Breast cancer cells
were treated with the pharmacological inhibitor of proteasome, MG132, for 48 h. Expression of survivin was determined by Western blotting. (B) Breast cancer cells
were treated with indicated concentrations of SAHA for 72 h and the expression of 26S proteasome was analyzed by Western blotting. (C) Breast cancer cells were
treated with SAHA for 72 h and the intracellular proteasome activity in the treated cells were assessed using proteasome activity fluorometric assay kit. Experiment
was repeated three times. A statistically significant difference in the proteasome activity in cells treated with SAHA vs. without SAHA (control) is denoted by “*” (p <
0.05). (D) MCF7 cells were treated with SAHA for indicated durations and expression of Hsp90 was determined by Western blotting. Signals in the Hsp90 blots (of all
repeats) were quantitated and a graph was generated to show the effect of SAHA on the expression of Hsp90. A statistically significant difference in the expression of
Hsp90 in cells treated with SAHA vs. without SAHA (0 h) is denoted by “**” (p < 0.01). (E) Breast cancer cells were transfected with scramble, HDAC3, HDAC1, or
HDAC2 siRNA for 72 h. Expression of various proteins was determined by Western blotting. (F) Breast cancer cells were treated with BML281 for 24–72 h. Expression
of different proteins was determined by Western blotting. Signals in the Hsp90 blots (of all repeats) were quantitated and a graph was generated to show the effect of
BML281 on the expression of Hsp90. A statistically significant difference in the expression of Hsp90 in cells treated with BML281 vs. without BML281 (0 h) is denoted
by either “*” (p < 0.01) or “***” (p < 0.001).
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FIGURE 6 | Proposed mechanisms of SAHA in the expression
regulation of survivin in human breast cancer cells. Arrow indicates
activation; Bar indicates inhibition.
of the lysophosphatidylcholines, decreased HDAC3 expression
and suppressed the binding of HDAC3 to the promotor of
survivin in chronic myelogenous leukemia K562 cells in vitro
(Jung et al., 2013). Therefore, it is possible that inhibition of
HDAC6 and HDAC3 all contributed to the SAHA induced
survivin acetylation, nuclear translocation, and the subsequent
protein degradation in breast cancer cells. Inhibition of HDAC3
further contributed to the SAHA induced gene transcription
reduction of survivin in the treated cells (Figure 6).
Besides inducing the acetylation and nuclear translocation
of survivin protein, SAHA also increased the expression of
26S proteasome in the tested cell lines. It is well-known
that survivin associates with Hsp90 via an interaction that
involves the ATPase domain of Hsp90. Binding of Hsp90
prevents survivin undergoing ubiquitination and the subsequent
protein degradation by proteasome (Fortugno et al., 2003).
Intriguingly, inactivation of HDAC6 has been shown to induce
Hsp90 hyperacetylation, resulting in a loss of chaperone
activity (Kovacs et al., 2005). In our study, inhibiting HDAC6
decreased the expression of Hsp90 in MCF7 and MDA-
MB-231 cells. Therefore, SAHA might down-regulate survivin
expression through transcriptional modulation and multiple
post-translational mechanisms including increases in the rate
of proteasomal protein degradation, the amount of protein
acetylation, and the level of nuclear translocation viaHDAC6 and
HDAC3 inhibitions (Figure 6).
In conclusion, our study reveals that SAHA has potential for
the management of various breast cancer subtypes regardless
of the expression of ER and tamoxifen sensitivity. Our
study also reveals that down-regulation of survivin gene
transcription and protein stability by the inhibition of HDAC6
and HDAC3 might play important roles in both SAHA-
induced autophagy and SAHA-reduced cell viability in breast
cancer cells. Our findings emphasize the complexity of the
regulatory roles in different HDAC isoforms and potentially
assist in predicting the mechanism of novel HDAC inhibitors
in targeted or combinational therapies in the future (Shi et al.,
2010).
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Supplementary Figure 1 | Resveratrol induces the formation of AVOs in
breast cancer cells. MCF7 and MDA-B-231 breast cancer cells were treated
with 1x IC50 resveratrol for 72 h and subsequently stained with MDC. AVOs in
cells were observed under a fluorescence microscope. Red arrows indicate green
fluorescence puncta formation.
Supplementary Figure 2 | Down-regulation of different HDAC isoforms
induces differential effects on the expression of survivin and conversion
of LC3B-II in breast cancer cells. (A) MDA-MB-231 and (B) MCF7 cells were
transfected with either scramble siRNA or different HDAC isoforms specific siRNA
for 48 h. Expression of different proteins and conversion of LC3B-II were
determined by Western blotting.
Supplementary Figure 3 | Inhibiting HDAC3 and HDAC6 decreases survivin
expression and increases LC3B-II conversion in Sk-Br-3 cells. Sk-Br-3
breast cancer cells were treated with either RGFP966 or BML281 and the
expression of various proteins was determined by Western blotting.
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